Hearing News Watch

CHADDS FORD, PENNSYLVANIA – CQ Partners has announced that Olympian and cancer survivor Chaunté Lowe will deliver the keynote address at the industry event, Reconnect ’25. Lowe will kick off Reconnect “with her positive, can-do attitude, empowering attendees throughout the event”. Reconnect ’25 will take place from February 27 to March 2, 2025, at the Omni Amelia Island Resort in

SEATTLE, WASHINGTON — Sound Pharmaceuticals has announced the completion of the Phase 3 clinical trial for SPI-1005, a novel anti-inflammatory treatment for Meniere’s Disease (STOPMD-3). SPI-1005, an oral capsule taken twice daily, is the only potential therapeutic to show significant improvement in hearing loss and tinnitus in Meniere’s Disease patients, as demonstrated in two previous studies. The STOPMD-3 study enrolled

MILAN, ITALY — Amplifon S.p.A. has reported robust financial results for the first half of 2024, demonstrating significant growth in revenues and profitability. The company achieved consolidated revenues of €1.177 billion (approximately $1.28 billion USD), marking an 8% increase at constant exchange rates and a 5.7% increase at current exchange rates compared to the first half of 2023. This growth

COPENHAGEN, DENMARK – Oticon A/S has launched a clinical research partnership with the Division of Audiology at Detroit, Michigan-based Henry Ford Health, one of the leading integrated and academic healthcare systems in the United States. The collaboration aims to generate valuable insights into post-fitting outcomes and hearing aid user experiences. The Oticon Clinical Research Team will work with Henry Ford

Researchers have made significant progress in understanding how to reduce the harmful side effects of cisplatin, a common chemotherapy drug. Cisplatin is known for its effectiveness against various cancers but also for its severe side effects, especially hearing loss (ototoxicity) and kidney damage (nephrotoxicity). A recent study, led by a team from the National Institutes of Health (NIH) and other

EDEN PRAIRIE, MINNESOTA – Starkey has announced that the company has been awarded the prestigious 2024 National Access Award by the Hearing Loss Association of America (HLAA) last month. The award was presented at the recent HLAA Convention in Phoenix, Arizona and accepted by Dave Fabry, Ph.D., Starkey’s Chief Hearing Health Officer. The HLAA National Access Award was presented to Starkey in

The conference program for the 68th International Congress of Hearing Aid Acousticians is now available, featuring exciting lectures from outstanding speakers. This year, the focus is on Denmark, the partner country, highlighting their contributions to the field. Participants in the 68th EUHA Congress, set for October 16-18, 2024, in Hanover, can expect a comprehensive program featuring the latest in hearing

Researchers have uncovered significant findings linking microplastic exposure to hearing loss and balance issues in mice. The study, published in the Journal of Hazardous Materials, delves into the potential health risks posed by microplastics, particularly polyethylene (PE), a common plastic found in various consumer products. The study, led by Javeria Zaheer and colleagues, investigated the effects of microplastic polyethylene on

Washington, D.C.— The American Cochlear Implant Alliance (ACI Alliance) recently elected new board members and thanked outgoing members during CI2024 Vancouver: 17th International Conference on Cochlear Implants and Other Implantable Technologies held earlier this month in Vancouver, Canada. The newly elected board members are: Kenneth H. Lee, MD, PhD UT Southwestern Medical Center Professor, Department of Otolaryngology-Head & Neck Surgery

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company specializing in therapies for hearing loss disorders, has announced a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for the continuation of its NOTOXIS Phase 2a Proof-of-Concept (POC) clinical trial. This trial investigates the efficacy and safety of SENS-401 in preventing Cisplatin-Induced Ototoxicity (CIO). The DSMB